Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q4 FY2025 Earnings Presentation
40 slides from Dr. Lal Pathlabs's earnings presentation, Apr 25, 2025
Slide 1: Exchange filing cover letter
April 25, 2025 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Earnings P
Slide 2: Results Presentation for Q4 & FY25
Results Presentation for Q4 & FY25
Slide 3: Disclaimer
By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentations by the
Slide 4: Table of Contents
Table of Contents 4 DLPL - At a Glance 5 Q4 FY25 Performance Overview 7 Financials 8 Key Performance Highlights 12 Management Commentary 13 Corporate Overview 37 Shareholding 39 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Company’s business operat
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance 6,607 Patient Service Centers (PSC’s) 75+ years of experience in the 131 Mn patients serviced in last 5 field of diagnostics 5,012 years Pathology & Radiology tests; India’s Leading Comprehensive Test menu 40 NABL accredited Labs; & Trusted Diagnostics Company 2 CAP ac
Slide 6: Q4 FY25 Performance Overview
Q4 FY25 Performance Overview Q4 FY25 Q4 FY24 Rs. 603 crore Rs. 545 crore Revenue 10.5% Rs. 169 crore Rs. 145 crore EBITDA 16.9% Rs. 156 crore Rs. 86 crore PAT (Reported) 81.4% Rs. 115 crore Rs. 86 crore PAT (Ex. One 33.8% time adjustment) 6.8 MN 6.5 MN Patients 3.8% 20.9 MN 19.1 MN Samples
Slide 7: FY25 Performance Overview
FY25 Performance Overview FY25 FY24 Rs. 2,461 crore Rs. 2,227 crore Revenue 10.5% Rs. 696 crore Rs. 609 crore EBITDA 14.2% Rs. 492 crore Rs. 362 crore PAT (Reported) 35.9% Rs. 451 crore Rs. 362 crore PAT (Ex. One 24.6% time adjustment) 28.8 MN 27.6 MN Patients 4.2% 85.6 MN 78.2 MN Samples
Slide 8: Financials
Financials Particulars (Rs. Cr.) Q4 FY25 Q4 FY24 Gr % FY25 FY24 Gr % Revenue 603 545 10.5% 2,461 2,227 10.5% Material consumed 118 109 481 451 Employee benefit Expenses 115 106 482 425 Fees to collection centres 78 76 342 313 Other Expenses 123 111 460 428 EBITDA 169 145 16.9% 696 609 14.2% Margins
Slide 9: Key performance highlights
Key performance highlights ⚫ Revenue of Rs. 603 crore in Q4 FY25, a growth of 10.5% Y-o-Y; FY25 revenue of Rs. 2,461 crore, an increase of 10.5% Y-o-Y o Volume-led growth achieved through deeper penetration in core markets and calibrated expansion in newer regions of West & South o West region contr
Slide 10: Operating highlights
Operating highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +21 +1,876 +1,770 277 277 280 298 6,607 12,365 5,762 10,938 11,619 10,595 4,731 5,102 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 No. of Patients (Mn) No. of Samples (Mn) +8.5 +35.9 85.6 28.8 72.3 78.2 27.3 26.
Slide 11: Robust financial performance
Robust financial performance (INR Cr.) (INR Cr.) South Revenue India Others EBITDA, PAT and Return on Net Worth 2% West 6% Delhi & India NCR EBITDA PAT 14% 31% 696 Revenue by 609 Geography 490 492 East FY25 2,227 2,461 India 362 2,017 241 15% Rest of UP & UK FY'23 FY'24 FY'25 North 19% FY'23 FY'24 F
Slide 12: Robust financial performance (Cont’d)
Robust financial performance (Cont’d) Times (INR Cr.) Fixed Asset Turnover1 Cash and Cash Equivalents 1,229 12.3x • Self funded growth on 11.2x 10.1x account of strong cash flow 877 generation • Attractive fixed asset turnover 601 ratio given asset-light model • Current net cash position and interna
Slide 13: Management Commentary
Management Commentary Mr. Shankha Mr. Ved Prakash Goel, (Hony) Brig. Dr. Arvind Lal, Banerjee, Group CFO & CEO – Executive Chairman Chief Executive International Business Officer Commenting on the performance, (Hony) Brig. Dr. Arvind Commenting on the performance, Mr. Shankha Banerjee, Commenting on
Slide 14: Corporate Overview
i | « af - D2 Lat Pathlals
Slide 15: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Established Pan-India Varied Unique and brand integrated Offerings successful coverage operating model 298 clinical labs (including National Reference Lab at Catalogue of 385 test panels, Scalable model integrated Established consumer Delhi and Regional Reference through
Slide 16: Our Evolution
Our Evolution • First to set-up RT-PCR testing network in 2020 • Completed acquisition of Suburban Diagnostics in 2021 • Higher contribution from • Expanded South ecosystem Rest of India business & through Bengaluru Reference Lab • Investment by TA focus on bundled test and network of Hub & Satellit
Slide 17: Most trusted healthcare brand in Diagnostic Services
Most trusted healthcare brand in Diagnostic Services Lab/PSCs Pillar of a Strong Brand Sample Collection Home Online • Accreditations from Registration CAP, NABL and ISO Offline • Centrally Accreditations Walk-in administered customers surveillance Diverse and account for programs Single large Natio
Slide 18: Collection network
Collection network LPL’s scalable business model provides strategic advantage for expansion and consolidation National Reference Lab & Regional Ref. Lab Regional Reference Lab Single brand pulls patients Clinical Labs (Testing/Collection) Walk-in customers account for Patient Service Centers Pick-up
Slide 19: Digital Touchpoints across patient journey
Digital Touchpoints across patient journey ⚫ Patient App/Website – Order Booking, Reports, Find Nearby Center, Test Info, Expected ⚫ Historical Trends time of report, Live order status, App Notifications SAMPLE COLLECTION ⚫ Live tracking of samples, ⚫ Cumulative Reporting inter & intra city, cash ⚫
Slide 20: ABDM - All Milestones achieved, DLPL among early adopters
ABDM - All Milestones acheived, DLPL among early adopters Ayushman Bharat Digital Mission aims to create a National Digital Health Ecosystem to bridge the existing gap amongst different stakeholders of Healthcare ecosystem through digital highways. The mission also enables interoperability and porta
Slide 21: Vision, Mission & Values
Vision, Mission & Values VISION MISSION VALUES Be the most To be an undisputed Customer First trusted healthcare market leader by providing Ethics & Integrity partner, enabling accessible, affordable, healthier lives timely and quality Quality healthcare, diagnostics, Accountability applying insight
Slide 22: DLPL Strategy for future growth
DLPL Strategy for future growth ⚫ Follow cluster city approach Drive increased volume in high- ⚫ Enhance presence in Maharashtra especially potential West & South India; Hub Mumbai labs in North ⚫ Launched Reference labs in Bengaluru & Mumbai ⚫ Established specialty verticals: Genevolve Enhance high
Slide 23: Leveraging digital infrastructure to make life easier for patient
Leveraging digital infrastructure to make life easier for patient New Website Launch Reco.ai Logistics App Wallet One Registration Chatbot 2.0 • New age user intuitive • LPL’s own AI based • Machine Learning • Senior Citizen Wallet: • One unified platform • New version of website. Recommendation bas
Slide 24: Genevolve: Genetic Testing Division
Genevolve: Genetic Testing Division Onco Genomics Neuro Genomics Rare Disease Reproductive Genomics Launched First Successful On-boarded Introduced a in India, Dedicated State of art completion of latest NGS range of “Business technologies instrument “Screening Development “5 years of Launch” “cfDNA
Slide 25: First in South Asia - Amyloid Typing
First in South Asia - Amyloid Typing Amyloid Protein Typing Facility Under the Guidance of the National Amyloidosis Centre, London (UK) 24
Slide 26: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 98.0% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.3% for Satellite Labs CAP accreditation 2 labs, NABL accreditation 40 Labs 100+ Quality Digitally improvement enable
Slide 27: Quality Control
Quality Control Laboratory excellence Capability building NABL 133 PROJECT NEEV- implementation LPL proficiency self learning testing program initiative for launch phlebotomists D L Shah Gold Award for Test Analytical Quality LPL Project Quality education Recommend Scoring & ‘Improving Laboratory pr
Slide 28: Control Tower Implementation
Control Tower Implementation “Control Tower” implementation provides a complete visibility of Patient samples across the sample processing lifecycle. The insights will help the business users to reduce delay and improve processing leading to better customer service. Control Tower Teams Front Desk Lo
Slide 29: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Real time 30 minutes slot D2C- Automated lead visibility & booking for the management patient Auto Routing engine to Digital ID card & dynamically allocate ratings of Phlebo to the booking to nearest the patient available phlebotomist Variable model wh
Slide 30: Key ESG Initiatives
Key ESG Initiatives Commissioned 3.18 MW Solar System for generating the green energy Installed R32 refrigerant operated Inverter AC for Conserving ozone layer Use of Electric bikes for sample collection All labs are equipped with Effluent Treatment Plant for wastewater treatment Saved 16,43,858 Kg
Slide 31: Cyber Security Capability
Cyber Security Capability Data Loss Prevention Threat Intelligence • State-of-the-art data loss prevention • Threat intel platform to monitor the surface, technology to monitor and prevent the deep and dark web for credential disclosures, disclosure of information data leaks, frauds and scams • Data
Slide 32: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Vandana Shankha Dr. Arvind Lal Lal Banerjee Executive Whole-time Chief Executive Chairman Director Officer Ved Prakash Munender Jai Prakash Manoj Garg Goel Soperna Meena Group Chief Chief Group Chief Group CFO & Information & Operating Human CEO – Digita
Slide 33: Investment Highlights
Investment Highlights
Slide 34: Investment Highlights
Investment Highlights Demonstrated high scalability, Best-in-class and consistent integrated through centralized financial track record with IT platform for network healthy return ratios expansion Consolidating Fundamental levers in place Largest consumer healthcare presence in West to drive expansi
Slide 35: Indian Healthcare Services is a large and growing opportunity
Indian Healthcare Services is a large and growing opportunity ~1.51 bn 2.5% Per capita current expenditure on health in $ terms (2020)4 India’s expected population in Government Expenditure on Globally: Total Healthcare Expenditure is 10.9% of GDP 20301 healthcare (as % of GDP) in FY255 India 56.6 C
Slide 36: Drivers of India diagnostic services market
Drivers of India diagnostic services market Diagnostic Services Industry Size Growth Drivers Demand for lifestyle Increase in Expected ~Rs. 1,200 Bn diseases related evidence-based 8-10% CAGR services to grow treatments ~Rs. 774 Bn FY23 FY28E Rapid Focus on Urbanization preventive diseases and welln
Slide 37: Diagnostic Services industry continues to remain highly fragmented
Diagnostic Services industry continues to remain highly fragmented Highly Fragmented Industry Region wise Revenue 76% Standalone Centres 42-46% Regional Chains 55% Diagnostic 16-20% Chains 24% Multi-Regional 45% 36-40% Hospital Rural Urban Based Labs Diagnostic penetration in rural market is lower,
Slide 38: Shareholding as of 31st March, 2025
Shareholding as of 31st March, 2025 24.10% FPI’s & NRI’s 53.91% Promoter and Promoter Group 8.95% Others 13.04% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 37
Slide 39: Key Awards & Recognition
Key Awards & Recognition Diagnostic Chain of the Year – West Gold Award Awarded by the Top 100 Global Most QCI – D. L. Shah Quality Business Standard Star Best Brands Healthcare GAPIO Excellence in prestigious Healthcare Loved Workplace 2023 Awards - 2022 SME of the year 2022 2022 Diagnostics Award
Slide 40: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) For further information please contact: Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. Ved Prakash Goel It has an integrated nationwide network, where patients and healthcare providers are offered